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41. Introduction
With an incidence of 1-5% preeclampsia is a major cause of fetal and maternal morbidity (1). 
Manifested generally in the mid-to-late stages of gestation, preeclampsia is diagnosed on the 
basis of three clinical signs: hypertension, proteinuria and edema. Severe and acute 
complications include a convulsive condition called eclampsia and/or a condition with 
multiorgan dysfunction, most often appearing as Hemolysis, Elevated Liver Enzymes and 
Low Platelet count (HELLP) syndrome (2). Risk for the development of the disease is 
increased in the case of primiparity, work-related psychosocial strain during pregnancy, bad 
social background, the mother’s own low birthweight, prematurity and young age (3, 4, 5). 
Chronic hypertension, diabetes and obesity predispose women to preeclampsia (6, 7). Severe 
early-onset preeclampsia is often associated with clotting abnormalities, such as the Leiden 
mutation of factor V, prothrombin 20210A allele, protein C, protein S and antithrombin 
deficiency, possibly leading to a more accelerated course of the disease by inducing an 
abnormal interaction between endothelial cells, platelets, leukocytes, and plasmatic factors, as 
well as causing intervillous or spiral artery thrombosis and consequently inadequate placental 
perfusion (6, 8,9).
The onset and progression of the disorder are unpredictable, and the only entirely effective 
treatment for preeclampsia/eclampsia is termination of the pregnancy. The etiology and 
pathogenesis of the disease are still unknown. Since preeclampsia may occur in women with 
abdominal pregnancies, it is not likely or at least not necessary for the uterus to play a part.
2. Etiology and pathomechanism of preeclampsia
2.1. Two-stage disorder theory
According to the widely accepted theory suggested by Redman and Roberts, preeclampsia is a 
two-stage disorder (10). The illness derives primarily from a placental ischemia (11,12). Poor 
placental perfusion, as tested in animals (13), either as a result of immunologically mediated 
abnormal implantation, excessive placental size or microvascular disease derived from pre­
existing hypertension, diabetes or other factors, predispose pregnancies to preeclampsia. 
Pregnancy induces the uterine spiral arteries to remodel into dilated uteroplacental vessels by 
an unknown mechanism called “physiological change” (14). During this process extravillous 
cytotrophoblasts invade the uterine endometrium and myometrium and migrate in a retrograde 
direction up the spiral arteries, transforming them into large-bore tortuous vessels of low 
resistance (15). This physiological remodeling process, characterized by a gradual loss of the 
5normal musculoelastic structure of the arterial wall, is required for a successful pregnancy and 
spiral artery transformation failure has been well documented in preeclampsia (16,17).
Consequent (secondary) clinical symptoms reflect a generalized vasoconstrictive disorder 
as a result of abnormal vascular endothelial function. These changes are similar to the changes 
observed in disseminated intravascular coagulation and hemolytic uremic syndrome. The 
serum levels of a certain adhesion molecule, the vascular cell adhesion molecule (VCAM-1), 
were found to be elevated. Higher VCAM-1 levels may represent a possible mechanism by 
which endothelial cells attract leukocytes, which cause endothelial cell damage (18). 
Disturbances in endothelial cell function may lead to elevated shear stress of erythrocytes, 
resulting in hemolysis, increased red blood cell turnover (19) and release of red blood cell 
content, all of which can aggravate endothelial damage. Furthermore, there is a breakdown in 
the balance between vasodilator substances such as prostacyclin, prostaglandin E2 and nitric 
oxide and the vasoconstrictors including angiotensin n, thromboxane A2, serotonin and 
endothelin (20,21). In preeclampsia, the placenta produces seven times more thromboxane A2 
than prostacyclin (21). As postulated by Roberts et al. (22), blood-borne products originating 
from a poorly perfused fetal-placental unit could injure or activate endothelial cells and the 
resultant changes in the function of these cells could activate intravascular coagulation and 
increase sensitivity to pressors. During the hypoxia-reperfusion injury of the ischemic 
placenta the enzyme xanthine oxidase, which has also been detected in the human placenta 
(23), generates superoxide anions. Xanthine oxidase is one of the main sources of reactive 
oxygen species in hypoxic tissues, and so it contributes greatly to consequent oxidative tissue 
injury (24). The transfer of oxidative stress processes from the intervillous space to the 
systemic circulation may involve activated leukocytes, stable products of lipid peroxidation 
and even cytokines. Such cytokines, originating from the foci of placental hypoxia/ischemia, 
are tumor necrosis factor-a and interleukin-1 a and ß, the production of which were found to 
be elevated in hypoxic conditions of villous expiants from the human placenta (25). Similarly, 
the expression of placental cytokines, such as tumor necrosis factor-a, interleukin-1 ß and 
interleukine 10, was increased in the placentae of preeclamptic subjects (26).
Beyond the two-stage theory of the disease, three further hypotheses are currently at the 
heart of extensive investigation. It must be stressed that all of these theories, which attempt to 
explain the etiology and pathomechanism of the disease, are not mutually exclusive but 
probably interactive.
62.2. Very Low-Density Lipoprotein versus toxicity-preventing activity
Pregnancy in general, and preeclamptic pregnancy in particular, are associated with a marked 
hyperlipidemia. In preeclampsia, circulating free fatty acids are increased as early as 15 to 20 
weeks before the onset of the clinical disease (27). In compensation for increased energy 
demand in women with low albumin concentration, transporting extra non-esterified fatty 
acids from adipose tissues to the liver is likely to reduce albumin antioxidant activity to a 
point at which very low-density lipoprotein toxicity is expressed and triglyceride 
accumulation occurs in endothelial cells (28). As suggested by Lorentzen et al., when 
placentally derived endothelial disturbing factors, like lipid peroxides and trophoblastic 
components, are released into the maternal circulation, their effects on the endothelium may 
be enhanced by the hyperlipidemia-mediated activation or “sensitization” of the endothelial 
cells (29). As further support for the involvement of the lipid metabolism in the 
pathomechanism of preeclampsia, common coding sequence variations in the lipoprotein 
lipase gene have been shown to cause a substantially increased risk of preeclampsia (30). A 
recurrent theme is that free radical reactions, promoted by a “cross-talk” between the diseased 
placenta and maternal dyslipidemia, promote a vicious cycle of events that render cause and 
effect difficult to distinguish but likely contribute to the progression of preeclampsia (31). In 
preeclampsia increased red blood cell turnover can also be detected, as demonstrated by its 
indicators (19). Since heme derivatives may mediate lipoprotein oxidation and consequently 
endothelial damage, hemolysis may be an additional factor in the pathogenesis of the disease 
(32,33,34).
2.3. Immune maladaptation
Epidemiological evidence suggests that immune mechanisms ought to be involved in the 
etiology of preeclampsia (35, 36, 37). Genuine preeclampsia is primarily a disease of first 
pregnancies. A previous normal pregnancy is associated with a markedly lowered incidence 
of preeclampsia. Even a previous abortion provides some protection. The protective effect of 
multiparity, however, is lost with change of partner: thus, preeclampsia may be a problem of 
primipatemity rather than primigravidity (36).
The decidua contains an abundance of cells of bone marrow origin as is demonstrable by 
their cell surface antigen expression (CD45). These antigens are designated by their CD 
number, an arbitrary number assigned to each Cluster of Differentiation. In the late secretory 
7phase of the endometrium an unusual population expressing CD56, a marker of peripheral 
blood large granular lymphocytes, becomes dominant. These uterine large granular leukocytes 
resemble natural killer (NK) cells but do not express such strong NK cell activity as pe­
ripheral blood NK cells. About 75% of decidual cells express CD45, reflecting their bone 
marrow origin (i.e. 45% uterine large granular leukocytes, 19% macrophages, and 8% T 
cells). As pregnancy progresses, the number of macrophages and T cells remains constant but 
the number of uterine large granular leukocytes declines dramatically (38, 39, 40). The 
immunologically competent cells of the decidua may be important in the regulation of 
cytotrophoblast invasion (41).
What can be the link between immune maladaptation and endothelial cell activation in 
preeclampsia? The decidual cells of bone marrow origin can be activated and release 
mediators that may interact with endothelial cells. Such mediators most often regarded as 
etiological are cytokines and oxygen free radicals.
2.3.1. Involvement of Human Leukocyte Antigens (HLA) in the development of 
preeclampsia
In preeclamptic women and in their spouses there is a greater homozygosity at the HLA B 
locus (42). Also, antigen sharing at the A and B loci and HLA DR4 is greater between 
affected women and their spouses (43). The inducibility of TNF-a is HLA class II dependent, 
thus also providing a possible role for the HLA system.
On the other hand, so far the numerous studies on the role of the HLA system in 
preeclampsia have failed to lead to the detection of any definite influence (1). Wilton et al. 
(44) were able to rule out the linkage of maternally expressed susceptibility genes to the HLA 
region, but fetal involvement must still be taken into consideration (45). Preeclampsia is 
unlikely to be the simple result of excessive HLA antigen sharing between mother and fetus, 
as was first thought, but a more complex mechanism involving feto-matemal compatibility 
cannot be excluded. HLA-A, -B and -C genes are blocked in the placental trophoblast cells 
(46). Instead, HLA-G, a non-specific HLA I group antigen, is expressed by the trophoblast 
cells (47). We may suppose that HLA-G is involved in the development of immune tolerance 
(48). Although there was no detectable relationship found between susceptibility to 
preeclampsia or being bom of a preeclamptic pregnancy and the HLA-G genotype (49), a 
more recent study revealed that an absence/reduced level of HLA-G expression in extravillous 
8cytotrophoblasts is associated with preeclampsia. According to this study, trophoblasts 
lacking HLA-G may be vulnerable to attack by the maternal immune system (50).
Many of the findings concerned with the role of HLA in the development of preeclampsia 
are inconsistent or contradictory. However, further examinations of HLA in preeclampsia are 
likely to find new links.
2.4. Genetics of Preeclampsia
2.4.1. Role of Genetics: family analysis, genomewide analysis
According to epidemiological studies, preeclampsia/eclampsia has a strong familial 
component (51, 52, 53). Daughters of preeclamptic women have a higher chance of 
themselves developing preeclampsia/eclampsia. Phenotyping patients with preeclampsia is 
vital for any genetic study. In a genomewide screen of Icelandic families representing 343 
affected women, a significant locus was found on 2pl3 (54), while in another genomewide 
linkage study of preeclampsia/eclampsia evidence was found for a candidate region on 4q 
(55). With a mathematical analysis of three or four generations hypothetically either a single 
dominant gene with incomplete penetrance or a single recessive gene could fit the data (56). 
Still, it is unlikely that there is a single gene responsible for the pathogenesis of preeclampsia. 
We may, however, suppose that a cluster of polymorphisms, possibly in conjunction with 
environmental factors, predisposes one to the development of the disease. It is also likely that 
a fetal genetic contribution may also be involved in the pathogenesis: there is an increased 
risk of preeclampsia in women who become pregnant by a man who has already fathered a 
preeclamptic pregnancy in another woman (3).
2.4.2 Genetic factors possibly involved in the pathogenesis of preeclampsia/eclampsia
2.4.2.1. The role and the effect of genetic variability in the renin-angiotensin system
All major components of the renin-angiotensin system (renin, prorenin, angiotensinogen, 
angiotensin (AT) I, angiotensin n, angiotensin converting enzyme (ACE) and angiotensin 
receptors) are present in the human placenta and related tissues, forming one of the examples 
of the recently accepted local renin-angiotensin system (57, 58). In this system, AT II can act 
in an autocrine/paracrine fashion (59): it can stimulate angiogenesis and also is capable of 
antiproliferative actions by mediating the inhibition of endothelial cell proliferation (60, 61). 
Since renin, ACE and AT receptor 1 are all expressed in and around remodeling spiral arteries 
(57), the known actions and presence of the renin-angiotensin system suggest that the local 
9spiral artery renin-angiotensin system may play a role in the pregnancy-induced remodeling 
of these vessels. During the last decade, the possible role of genetic variability in the 
constituents of the renin-angiotensin system in the pathogenesis of preeclampsia has been 
extensively examined:
Angiotensinogen: A significant association of preeclampsia with a molecular variant of 
angiotensinogen, M235T (threonine for methionine), was observed in a series of Caucasian 
women with pregnancy-induced hypertension (62). Moreover, heterozygous women were 
shown to exhibit a significantly elevated expression of the T235 allele compared to the M235 
allele. Further observations suggested that the elevated expression of the T235 allele in 
decidual spiral arteries may cause first-trimester atherotic changes leading to preeclampsia 
(63). On the other hand, the contribution of angiotensinogen gene polymorphism to the 
occurrence of preeclampsia/eclampsia seems not to be constant across populations (64).
ACE gene polymorphism: In two studies evaluating the effect of ACE insertion-deletion 
polymorphism on the incidence of preeclampsia/eclampsia, no evidence was found that the 
polymorphism of the ACE gene was associated with preeclampsia/eclampsia (65,66).
Renin In an investigation on two or three generations of affected females, although only in a 
relatively smaller number of families, gene restriction fragment length polymorphism did not 
exhibit linkage with preeclampsia/eclampsia (67).
AT receptor type 7; In a recent study, Morgan et al. found that allele and genotype frequencies 
in four polymorphic regions did not differ between normotensive and preeclamptic groups. 
However, two variants (a 573T variant in the coding exon of the receptor gene and a 
dinucleotide repeat polymorphism in its 3’ flanking region) showed a similar distortion of 
maternal-fetal transmission (68). According to this finding, the ATI receptor transmission in 
the fetus may contribute to the etiology of preeclampsia.
2.4.2.2. Endothelium-derived nitric oxide synthase (eNOS)
Of the three isoforms of NOS, eNOS is widely distributed in the placental tissue (69), 
producing nitric oxide (NO), a potent vasodilator and inhibitor of platelet aggregation (70). 
Although eNOS is expressed by syncytiotrophoblasts, no proof of expression was found in the 
case of extravillous cytotrophoblasts at any time during invasion (71). This fact suggests that 
NO is unlikely to contribute to spiral artery dilatation. On the other hand, reduction of eNOS 
activity was detected in preeclamptic placentae (72, 73), implicating the eNOS gene in the 
pathophysiology of preeclampsia/eclampsia. A linkage study using preeclamptic families
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reported evidence for a preeclampsia/eclampsia susceptibility locus in the eNOS region on 
chromosome 7q36 (74). This, however was not confirmed in a recent repetition study using 
the same markers (75), while in another recent linkage study using 25 microsatellite markers 
from chromosome 7, a strong suggestion of linkage was found for one marker, D7S1805 (76). 
The results of these examinations raise the strong possibility that a putative 
preeclampsia/eclampsia susceptibility locus may be located on 7q36.
2.4.23. Is preeclampsia a mitochondrial disease?
In the late 1980’s Tobergsen and his co-workers observed that a high incidence of 
preeclampsia was present in a family with mitochondrial dysfunction (77). The same research 
group found that mutations in the mitochondrial transfer ribonucleic acid genes in two 
families were also associated with preeclampsia (78). Differentiation of the early embryonic 
trophoblast (which forms the placenta) and invasion of the trophoblast into the maternal 
endometrium are highly energy-consuming processes, requiring cell migration and synthesis 
of a large variety of molecules. It is therefore a reasonable speculation that a defect in the 
energy-producing system of the trophoblasts may impair normal placentation. Although the 
involvement of mitochondria in the pathogenesis of preeclampsia is possible, population­
based studies do not support the hypothesis (3,37): while mitochondrial genes are transmitted 
through the mothers, paternal genes clearly contribute to the risk of preeclampsia.
2.5. Unifying hypotheses (Figure 1)
Endothelial cell dysfunction appears to be the final common pathway of preeclampsia, yet the 
etiology of the disease remains obscure. Genetic factors are involved; however, it is likely that 
there is not one major preeclampsia gene but several genetic factors associated with maternal 
susceptibility. Placental ischemia and increased syncyciotrophoblast deportation probably 
represent an end-stage disease phenomenon. Immune maladaptation and the genetic conflict 
hypothesis are hypotheses that are congruous with data on the effects of changing partners 
and the protective effect of sperm exposure. Presence of an abundance of decidual leukocytes 
and the complex cytokine network underlines the pivotal impact of a correct fetal-maternal (or 
paternal-maternal) interaction. Leukocyte-, lipoprotein- and cytokine-mediated oxidative 
stress, caused by immune maladaptation or a genetic conflict, fits with data on cytokines, 
oxidative stress, lipid changes, and the type and chronologic sequence of endothelial cell 
dysfunction in preeclampsia.
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3. Animal models developed and used in the examination of preeclampsia
Although animal models for preeclampsia are no alternative to clinical studies, they are 
furthering our understanding of pathophysiology in numerous areas. There are several models, 
which mimic the human disease. In these models most characteristic symptoms of the disease, 
such as proteinuria, hypertension and fetal growth retardation, are present. However, since the 
etiology of preeclampsia remains unclear, it is doubtful that the artificial induction of the 
disease resembles the etiologic factors of human preeclampsia to any extent.
3.1. Preeclampsia-like conditions produced by NOS inhibition
NO, synthesized by endothelial cells from the amino acid arginine, plays a pivotal role in the 
maintenance of normal vascular tone (79). In the pathomechanism of preeclampsia, reduced 
eNOS activity plays an important role; however, its primary role is debated (2.4.2.2.). Acute 
blockade of NO synthesis by arginine analogues, such as L-nitro-arginine methylester (L- 
NAME), leads to transient but marked hypertension in both gravid and non-pregnant rats (80). 
After chronic administration of L-NAME either enterally or parenterally, rats demonstrated 
hypertension, proteinuria, glomerular injury and decreased platelet count (81, 82). Intrauterine 
growth retardation was also present in the pups of the treated animals (81, 82). The model can 
be easily reproduced, making it appropriate to test various therapeutic strategies. On the other 
hand, since the exact role of reduced eNOS activity in preeclampsia remains unclear, the 
pathomechanism of the experimental illness may differ greatly from the human disease.
3.2. Induction of a preeclampsia-like disease by ultra-low dose endotoxin infusion.
In the mid 1990s, rats infused with an ultra-low dose of endotoxin were shown to express 
relevant features of preeclampsia (83, 84). Endotoxin infusion resulted in a decrease of pup 
weight and number, as well as causing an increase in mean arterial pressure when compared 
to control animals. The model is based on the observation that preeclampsia shares a number 
of pathophysiologic phenomena with the so-called generalized Shwartzman reaction, which 
can be induced by endotoxin (85). Although endotoxin is unlikely to play a pathogenetic role 
in the development of preeclampsia, it has been suggested that the two diseases may share a 
final common pathway.
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3.3. Experimental preeclampsia produced by chronic constriction of the lower aorta.
This model is based on the theory that preeclampsia is a disease characterized by an increase 
in vascular tone associated with reduced uteroplacental flow leading to a breakdown in the 
balance of vasodilators and vasoconstrictors. Reduction of the lower aorta pressure/uterine 
blood flow resulted in hypertension, proteinuria and glomerular endotheliosis similar to 
human preeclampsia in several species, e.g. in rabbits, dogs and primates (13, 86, 87). The 
syndrome evoked in experimental conditions resembles preeclampsia. However, the primary 
mechanisms (placentation errors and causes of placentation errors) resulting in uterine artery 
constrictions differ. Thus, the model mimics the second phase of the illness.
3.4. Studies on the sheep model of preeclampsia
Pregnant ruminants, especially sheep, after 2-3 days of fasting and a consequent decrease of 
blood glucose levels, a significant elevation in blood pressure as well as increased proteinuria, 
may exhibit decreased uteroplacental blood flow and decreased glomerular filtration rate (88, 
89, 90). Histological alterations of the kidneys and liver are similar to that of human 
preeclampsia. Unlike in human preeclampsia, disturbed carbohydrate metabolism 
(hypoglycemia and ketonemia) is always present in this model. The symptoms in fasted ewes 
are not entirely identical to the human disease and may have different physio-pathological 
points. However, the illness in sheep mimics the human disease, and it can be induced 
through simple food withdrawal, without causing any artificial change in the animals’ 
organism, thus facilitating an investigation of pathomechanical alterations from the onset of 
the disease.
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4. Aims of our studies
— We wanted to reproduce the sheep model of preeclampsia, so as to examine the 
pathomechanism of the disease.
— Since increased erythrocyte turnover is present and may be involved in the 
pathomechanism of endothelial damage in human preeclampsia, we examined the occurrence 
of hemolysis and the onset of protective biochemical processes in the sheep model, whether 
they precede or follow the appearance of the first symptoms of the illness.
— We planned to examine the effects of two methylxanthines, allopurinol and pentoxifylline 
on the occurrence of biochemical and clinical signs of preeclampsia in the sheep model. Since 
allopurinol inhibits the enzyme xanthine oxidase and pentoxifylline improves 
microcirculation, consequently decreasing red blood cell damage, we hypothesized that both 
compounds may have inhibitory effects on the development of symptoms.
— In the human study our aim was to measure the activity of xanthine oxidase, one of the 
main sources of reactive oxygen specimens, in patients with mild pregnancy hypertension, so 
as to assess if there was any measurable elevation in the enzyme activity in vivo.
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5. Examinations concerning the pathogenesis of preeclampsia
5.1. Studies on the sheep model of preeclampsia
Subjects and Methods
Animals
The experiment was performed at the animal stables of the Debrecen Agricultural University 
Veterinary College, located in Hódmezővásárhely, Hungary. Before starting the study, a 
permit was obtained from the Albert Szent-Györgyi University Committee for Ethics in 
Animal Experiments (permit no. ÁTB 83/1993).
Twenty pregnant merino ewes at the gestational age of 130-135 days (terminus: 142-145 
days) were randomly divided into the following groups of 5 animals each: control; fasting; 
fasting, pentoxifylline (PTX)-treated (15 mg/kg/die, per os, divided into two doses, 
administered from day 0 to delivery); and fasting, allopurinol (AP)-treated (20 mg/kg/die, per 
os, divided into two doses, administered from day 0 to delivery). Prior to the experiment, 
during their pregnancy, the animals were fed hay. Water was supplied ad libitum. Before 
starting the dietary intervention animals were habituated to the stables. The pathomechanism 
of the disease was examined during a food withdrawal period (for 4 days), followed by a 
period of refeeding (for 3 days). The diagnosis was established according to the occurrence of 
symptoms: muscular tremors, increased proteinuria, hypertension, low platelet count and 
elevated liver enzymes.
Measurements
Ten ml of heparinized blood were collected by the direct puncture of the external jugular vein 
8 times: at the very beginning of fasting and at 24-hour intervals until the third day of 
refeeding (days 0-7). Blood was centrifuged immediately (10 minutes at 4°C, 1500 rpm).
Since sheep platelets are smaller than human thrombocytes, they could not have been 
measured effectively using hematological automates; thus, the platelet count was determined 
using a Buerker’s chamber and a polarization microscope.
Plasma biochemistry studies
Plasma glucose (glucose-oxidase/peroxidase enzymatic test), calcium (flame photometry), as 
well as creatinine (Jaffe’s method), urea-nitrogen (UV-test), albumin (bromcresol-green 
method), bilirubin (Jendrassik-Gróf method), glutaminate-oxalate-transferase (GOT) and 
glutaminate-pyruvate-transferase (GPT) levels (enzymatic UV-test), were measured each day.
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Iron and total iron-binding capacity were assessed on days 0 and 5 (with batho-phenantroline- 
disulfonic acid).
Plasma hemoglobin/heme concentration was measured spectrophotometrically at 415 nm 
(Soret band) expressed in pmol/l, using smM415”m = 125 (91). 25 pl of plasma was diluted in 1 
ml of phosphate buffer saline (pH 7.4, 5 mM) and the extinction was measured at 415 and 
700 nm. The 700-nm value (at which wavelength hemoglobin/heme does not give extinction) 
was considered the blind control of the sample and was extracted from the 415-nm value. 
Plasma concentration of free thiols was estimated spectrophotometrically (reduction of 5,5’- 
dithiobis-2-nitrobenzoic acid, Sigma) (92).
Hypoxanthine, xanthine, uric acid and alloxanthine levels were determined using the high­
performance liquid chromatography method (93).
After the introduction of a ballooned catheter, urine samples were taken every day. Total 
protein and hemoglobin contents were measured.
Daily blood pressure readings were taken every day throughout the experiment. Blood 
pressure cuffs connected to a digital sphygmomanometer were placed on the left thoracic limb 
over the anterior cephalic artery, and pressure was recorded 3 times over a 30-minute period. 
Statistical analysis
Multiple-choice analysis of variance was assessed. Factors for the analysis were: days (0-7), 
groups (1-4) and animals (1-5, within the groups). Pairwise comparisons were performed 
using Tukey’s test. If p-values were less than 0.05, alterations were considered to be 
statistically significant.
5.2. Human examinations
Subjects and methods.
Subjects
Pregnant women with mild hypertension but without superimposed preeclampsia were 
detected at routine obstetric visits after 24 weeks of gestation. Sixteen subjects met the 
criterion of gestational hypertension, defined as an increase of 30 mmHg in the systolic or 15 
mmHg in the diastolic blood pressure as compared with the values obtained before 20 weeks 
of gestation, or an absolute blood pressure of >140/90 mmHg if the earlier blood pressure was 
not known (12). Neither proteinuria nor any impairment in renal function was observed 
(defined as >500 mg per 24-h urine collection, and physiological creatinine clearance values).
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Most patients (n=12) had concomitant hyperuricemia, defined as >330 pM uric acid (UA) in 
plasma. There was a >15 kg rise in body weight during pregnancy in 14 patients, and there 
was transient diabetes in 4 of them. Six patients were regularly treated with antihypertensive 
drugs (methyldopa or nifedipine) during the study period. Thrombocytopenia, increased 
packed cell volume and abnormal liver enzyme activity were not seen.
Fourteen women with a clinically normal pregnancy, matched for maternal age, parity and 
gestational age, but with a significantly lower body weight acted as pregnant controls. The 
control women were age-matched members of the laboratory staff.
This study was approved by the Committee for Ethics of the University.
Blood and urine samples
Blood was drawn into ice-preheated tubes and separated within half an hour, and the sera 
were stored frozen at -70 °C until assayed (within 6 days). Patients were asked to refrain from 
methylxanthine containing food and beverages before 48 hours of investigation. Blank urine 
was collected before the patients received a dose of caffeine (10 mg/kg). Urine was collected 
over a 6-h period after caffeine consumption.
Determination of concentrations and ratio of caffeine metabolites
Urine concentrations of 1-methyl-xanthine (1MX) and 1-methyl-urate (1MU) were 
determined by the high-pressure liquid chromatographic (HPLC) method described by Grant 
et al. (94) with some modifications by Kilbane et al. (95). After adjustment of each urine 
sample to pH = 3.5 with 6 N hydrochloric acid, a 2 ml aliquot was stored at -20 °C until 
assay. A 0.2 ml aliquot of each sample was saturated with 120 mg of ammonium sulfate. Six 
ml of chlorofomrisopropanol (85:15, v/v) was added, followed by 0.1 ml of internal standard 
(5-fluorouracil, 40 mg/1), and the tube was vortexed vigorously for 30 sec. After 
centrifugation at 2,500 g for 5 min at room temperature, the organic phase was evaporated to 
dryness under a gentle stream of nitrogen at 45 °C. The residue was redissolved in 0.4 ml of 
the mobile phase. A 20 pl volume of the sample was injected onto a Waters pBondapak^M 
phenyl 125 A 10 pm column (3.9x150 mm; Waters) in tandem with a reverse-phase 
octadecylsilane column (Super Pac Spherisorb ODS2; 5 pm, 4.6 x 250 mm; Pharmacia, 
LKB), eluted with 0.05% acetic acidrmethanol (88:12, v/v) at a flow rate of 0.8 ml/min, and 
the eluate was monitored by the absorbance at both 272 and 280 nm. The HPLC system 
consisted of the following components: a Pharmacia LKB Pump 2248, an Autosampler 2157 
and a Variable Wavelength Monitor 2141.
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Standard plots were constructed in which the integrated signal values (relative to the 
internal standard 5-fluorouracil) were related to known amounts of 1 MX and 1 MU in a urine 
sample processed as above. Because of the wide range of the urine concentrations of the 
metabolites, two calibration plots were used for each compound of interest. The plots were 
linear in the concentration ranges 1-10 pM and 10-100 pM. Subsequent urinary 1MX and 
1MU concentrations were calculated by interpolation from the linear standard plots. The 
minimum quantifiable concentration for the analytes in 0.2 ml of urine was 0.5 pM. The intra­
assay and interassay coefficients of variation at a concentration of 25 pM were in the ranges 
2.5-4.2% and 4.8-7.8%, respectively, and the accuracy was within ± 7%.
Xanthine oxidase (XO) activity index was used to characterize the functional XO activity, 
it was calculated as the molar ratios of 1MU/(1MX+1MU) (96).
Other biochemical methods
The carbon monoxide-hemoglobin (COHb), and total hemoglobin levels were estimated by 
Hemoximeter (Radiometer Copenhagen) within 15 min after venapuncture. Concentrations of 
COHb were given as a measure of increased red blood cell turnover (19).
Plasma concentrations of hypoxanthine (HX), xanthine (X) and UA were determined by a 
reverse-phase HPLC method and UV detector (Pharmacia LKB) (93). The plasma contents of 
the lipid peroxidation products, fluorescent lipids and conjugated dienes were also estimated 
(97). The level of free thiols (SH groups) in the plasma was measured with Ellman reagent at 
412 nm (92).
Statistical analysis
Normally distributed demographic data were compared between groups using the r-test for 
continuous variables and the test for categorical data. Because the distribution of both 
metabolites and calculated ratios were highly skewed, logarithmic transformation preceded 
the statistical analyses. Analysis of variance and Scheffe’s post hoc test were used. 
Correlations between parameters were characterized by calculation of the linear regression 
and correlation coefficients. The significance level for all tests was taken as p < 0.05.
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5.3. Results of the animal experiments
No significant difference was noted among the various groups at the onset of the experiment. 
Apart from transient decreases of plasma indirect bilirubin and GOT levels, control animals 
showed no significant change from their initial values (Table 1, Figures 2A, 2B, 2C, and 3A). 
In all the fasting animals, blood glucose levels decreased significantly, as early as 24 hours 
after the onset of food withdrawal, from 2.88-3.1 mmol/1 concentration and reached its bottom 
line level of 1.42-1.54 mmol/1 concentration (p<0.01) by the end of the 96-hour fasting 
period. After refeeding, glucose levels quickly rose and reached the 2.9-3.2 mmol/1 
concentration (the same as that of the control animals) 48 hours after refeeding. Blood 
calcium concentration also decreased from 2.28-2.4 mmol/1 and reached the minimum level 
by the end of the 4-day fasting period (1.88-1.61 mmol/1, p<0.01) without a significant 
difference between the fasting groups.
According to the conventional signs of pregnancy-induced preeclampsia (hypertension, 
proteinuria, tremors, elevation of serum creatinine and urea-nitrogen), the disease was present 
in all the fasting, non-treated animals (Table 1, Figure 2A). Plasma albumin concentration 
showed a slight decline, which became significant by day 4 only in the non-treated group. A 
significant drop in platelet count and a simultaneous increase in plasma GOT level by the end 
of the fasting period also occurred (Figures 2B, and 2C), while a significant increase of GPT 
activity could be observed by day 7: the plasma enzyme activity increased from the initial 
value of 20.02 ± 6.04 to 44.80 ± 14.21 IU/1 (mean ± standard deviation), while in the control 
group it stayed within the 15-25 IU/1 range.
In the case of PTX- and AP-treated, fasting animals pathological alterations of kidney and 
liver function parameters, blood pressure and platelet count were also present; however, these 
changes occurred later than in the fasting, non-treated group, and the changes were smaller, 
especially in the case of plasma GOT activity (Table 1, Figures 2 A, 2B, and 2C). The increase 
of GPT concentration was not significant in the treated groups. Plasma enzyme activity rose 
by day 7 from the initial values of 20.75 ± 5.89 IU/1 (PTX-treated, fasting) and 16.76 ± 5.72 
IU/1 (AP-treated, fasting) (mean ± standard deviation) to 31.4 ± 9.12 IU/1 (PTX-treated, 
fasting) and 31.9 ± 9.08 IU/1 (AP-treated, fasting). Although significant proteinuria could be 
detected, plasma albumin levels did not decrease significantly (Table 1).
Plasma free thiols declined from the initial value of 145-160 pmol/1 in all the fasting 
groups, and a significant (p<0.05) decrease occurred after 48 hours of food withdrawal. By 
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the end of the fasting period, plasma free thiols reached the bottom line level of 80-90 pmol/l 
(p<0.01) in the case of the fasting and fasting, PTX-treated groups, while in the case of the 
fasting, AP-treated animals the concentration of thiols decreased to a less significant level 
(104.5 ± 9.8 jxmol/1, p<0.05, mean ± standard deviation). After refeeding, elevation occurred 
in all three fasting groups; however, thiol levels did not reach that of the control animals.
Plasma free heme level, as the first predictive sign of the illness, showed a sharp elevation 
simultaneously with the decrease of glucose levels in the fasting group, and subsequently it 
remained slightly elevated (Figure 3B). The elevation of plasma heme content was smaller 
than in both of the treated groups, and a significant increase was postponed to day 2 (AP- 
treated group) and day 5 (PTX-treated group). In addition, there were somewhat higher levels 
and an earlier increase of plasma indirect bilirubin (by day 1) in the treated groups than in the 
fasting, non-treated group (day 2) (Figures 3C and 3D). The summarized molar plasma 
indirect bilirubin/(indirect bilirubin + plasma free heme) ratios as product/(product + 
substrate) ratios, which provided indirect evidence of heme oxygenase activity (the enzyme 
which degrades heme), were more favorable in the drug-treated, fasting groups, compared to 
the fasting, non-treated group. In the pentoxifylline-treated group this ratio was 0.296 ± 0.059, 
significantly higher (p < 0.05) than in the fasting, non-treated group (0.222 ± 0.060), while in 
the allopurinol-treated group it was non-significantly higher (0.259 ± 0.050) (mean ± standard 
deviation).
While plasma iron level practically did not change in the control group, in the case of the 
fasting groups, it showed a significant decrease, which was slightly larger in the 
methylxanthine-treated groups. Iron concentrations decreased from 24.6 ± 3.7 to 16.9 ± 2.8 
pmol/l in the fasting, non-treated group while from 24.9 ±1.1 and 24.4 ± 5.2 to 14.4 ± 2.0 and 
14.3 ± 3.8 in the PTX- and AP-treated groups by day 5 (mean ± SD). Although this decrease 
was not accompanied by the significant alteration of iron-binding capacity, a slight decrease 
could be observed toward the end of pregnancy in each group of animals. This decline was 
larger in the treated groups (from 54.5 ± 4.2 and 57.1 ± 8.0 to 45.7 ± 5.3 and 48.2 ± 2.3 in the 
PTX- and AP- treated animals) versus the control and fasting group (from 53.1 ± 2.0 to 50.8 ± 
6.8 and from 53.8±3.9 to 51.1 ±2.1 pmol/l) (mean ± SD).
Plasma hypoxanthine, xanthine and uric acid levels were similar in the control, fasting and 
fasting, PTX-treated groups: hypoxanthine and uric acid concentrations ranged between 4 and 
6 pmol/1, while xanthine levels remained between 1 and 2 pmol/l (sheep purine metabolism is 
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different from that of humans: the enzyme uricase degrades uric acid, and consequently uric 
acid concentrations are low). In contrast, in the case of AP-treated, fasting animals, an 
inhibition of xanthine oxidase occurred after 24 hours. Uric acid level was under 2 pmol/l 
throughout the treatment period, while hypoxanthine and xanthine concentrations ranged 
between 7 and 12 pmol/l. Plasma concentration of alloxanthine, an active metabolite of AP, 
ranged between 6 and 12 pmol/1.
Outcome of Pregnancy: In the non-fasting group all the animals delivered healthy lambs 
(three twins and two singleton lambs) at 10.6 ± 2.3 days after the beginning of the experiment 
(mean ± standard deviation). In the fasting, non-treated group, one ewe (carrying twin 
pregnancy) died in convulsions. Lambs were bom earlier than among the control animals (7.2 
±2.5 days). Two ewes aborted (twin lambs) and two gave birth to viable lambs (one singleton 
lamb and one twin pregnancy). In the PTX-treated, fasting group two singletons and one from 
each twin pregnancy survived (time of birth 8.9 ± 3.1 days after the beginning of the 
experiment). In the AP-treated, fasting group two singletons and two pairs of twin lambs 
survived, while one pair of twins died (birth at 8.6 ± 2.9 days).
5.4. Results of the human examinations
The demographic data of the study groups are shown in table 2. The concentration of free 
thiols showed a decrease even in the normotensive pregnant women. Elevated contents of 
fluorescent lipids and conjugated dienes were measured in the hypertensive patients as 
compared with either the normotensive ones or the non-pregnant controls (Table 3).
There was no difference in the whole blood hemoglobin or COHb concentrations as 
potential markers of increased red blood cell catabolism (Table 3).
The sum of the plasma concentrations of physiological purine metabolites (HX+X+UA) 
was increased in the pregnant women versus the non-pregnant controls (p<0.05). An 
increased level of UA, the end product of XO, was demonstrated in the hypertensive 
individuals, while the amounts of substrate for XO (HX) were also significantly higher in the 
normotensive pregnant subjects than in the non-pregnant controls (Figure 4).
A significant decrease in the urinary concentration of 1 MX, the caffeine metabolite serving 
as a substrate for XO, was measured in the hypertensive subjects without any decrease in the 
urinary concentration of 1MU, the product of XO (Figure 5). As a result the XO activity 
index, the molar ratio 1MU/(1MX+1MU), displayed a significant rise in this group (Figure 6).
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5.5. Discussion of the animal experiments
Previous studies have already revealed that fasting provoked a unique physiological situation 
in pregnant ewes: a 72-hour-long withdrawal of food caused a human preeclampsia-like 
syndrome, while non-pregnant animals showed neither biochemical nor hemodynamic change 
(89).
In our experiment some other pathophysiological features characteristic of human HELLP 
syndrome were also shown. Besides hypertension and renal disturbances (Table 1), a fall in 
platelet count and hepatic insufficiency were also measured (Figures 2A, 2B and 2C). 
Pentoxifylline (PTX) and allopurinol (AP) had beneficial effects on the development of 
experimental pregnancy-induced preeclampsia-like disease in ewes. While in the fasting, non­
treated animals, all the mentioned characteristics of the disease (hypertension, renal and liver 
function disturbances and low platelet count) were detected, and pathological changes were 
smaller and occurred later in the treated animals. A significant decrease in blood calcium 
levels was also present in this model, similar to previous reports (90); however the three 
fasting groups showed a similar decline, which was not accompanied with the parallel onset 
of symptoms.
The decrease of plasma free thiols - the first line of antioxidant activity, offering a non­
specific buffer to oxidative stress - was similar in all the fasting groups. Presumably, the 
plasma level of free thiols was affected rather by alimentation than by oxidative processes. 
The less significant decline in the AP-treated group may be a result of the inhibition of 
xanthine oxidase activity.
A significant increase in plasma hemoglobin/heme, prior to the development of the 
disease, proved that oxidative stress was the common result of increased oxidant activity and 
insufficient antioxidant capacity of the red blood cells resulting in hemolysis. Sheep red blood 
cells are extremely sensitive to oxidants because of their low antioxidant protective glucose-6- 
phosphate dehydrogenase (G6PD) activity (98). In fasting pregnant ewes a decline in the 
plasma glucose level occurred even after a short period because of the accelerated glucose 
metabolism. As a consequence of insufficient capacity of the hexose-monophosphate shunt, 
erythrocytes fail to regenerate oxidized glutathione (GSSG) to its reduced form (GSH).
An increased heme catabolism, estimated as a concomitant rise in plasma bilirubin levels, 
were also seen in fasting pregnant animals during the whole experiment (Figures 3B, 3C and
hted ihshuman pathology.
3D) as a signal of heme oxygenase enzyme activation (99). All the above-mentioned changes 
were in concordance with biochemical signs doc
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Plasma hemoglobin/heme levels increased later and less in both of the treated, fasting 
groups than in the non-treated, fasting animals, and higher concentrations of plasma indirect 
bilirubin levels were measured as early as day 1. Since PTX improves microcirculation 
oxygenation by improving the flexibility of the erythrocytes and decreasing blood viscosity 
(100), these effects of the drug may also improve placental microcirculation. Consequently, 
local hypoxia and hypoxic-reperfusion injury may be postponed. AP could also defend against 
local oxidative stress by specifically inhibiting the enzyme xanthine oxidase (101), the 
presence of which in the placenta has been proved (22,102).
Induction of heme oxygenase, a 32 kD oxidative stress protein, the rate-limiting enzyme in 
the catabolism of cellular heme indicated the protective processes of endothelial cells against 
heme toxicity. As it breaks down heme, it produces the antioxidant biliverdin, which is 
quickly reduced to bilirubin, which is also antioxidant (103). Iron and carbon monoxide are 
the two other products of the heme oxygenase enzyme reaction, the latter being a potent 
relaxant of vascular smooth muscle. Increased levels of carboxyhemoglobin, serum iron and 
bilirubin in severe cases of preeclampsia (19) were not only indicators of increased red cell 
turnover but also signals of induced oxidative stress protein activation.
In the case of the treated animals, the enhanced formation of bilirubin, compared to the 
fasting, non-treated sheep, refers to the better activation of heme oxygenase. Induced heme 
oxygenase activity, as an additional beneficial effect of PTX and AP, indicates more effective 
protective processes of endothelial cells against heme and also non-heme (iron) toxicity (99, 
103). Although we found no reference to AP or PTX inducing heme oxygenase synthesis in 
human or sheep endothelial cells, as xanthine derivatives, both compounds elevate the 
intracellular level of 3’,5’-cyclic-AMP (cAMP) via inhibition of phosphodiesterase. Recent 
articles have revealed that in both rat muscular smooth muscle cells and hepatocytes heme 
oxygenase gene expression was increased due to elevation of the intracellular cAMP level 
(104,105).
Studies in the mid 1990s showed that even small amounts of the highly reactive 
hemoglobin in plasma suffice to trigger oxidation of low-density lipoproteins, thus possibly 
damaging vascular endothelial cells (106). In addition, heme has a direct injurious effect on 
the endothelial cells (107). Heme is a physiologic iron chelate that could facilitate endothelial 
iron uptake in cultured endothelial cells (108). Iron-loaded cells become extremely sensitive 
to exogenous or endogenous oxidants. Vascular endothelium in contact with hemolyzing red 
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cells, might be rendered hypersusceptible to damage by adherent stimulated 
polymorphonuclear leukocytes or lipid peroxides (32,107,108).
Induction of heme oxygenase has been proved to be a rapid, protective antioxidant 
response to heme burden in different animal models of tissue injury in which enhanced 
oxidative stress is implicated (109,110, 111), and at the same time a signal of endothelial cell 
oxidative stress. Additional evidence for our hypothesis concerning hemoglobin as the direct 
cause of endothelial cell injury with consequent heme oxygenase activation was found in the 
endothelial cell cultures exposed to different acellular hemoglobin solutions (112). 
Furthermore, in cultured endothelial cells there was a dose- and time-dependent enhancement, 
after a certain lag time (24-72 h), in secretion of endothelin-1, a peptide with a potent 
vasoconstrictive effect and with higher concentration in preeclampsia (113), in response to 
erythrocyte lysates (114).
Endothelial injury caused by heme/hemoglobin resulting in hypersensitivity of endothelial 
cells to exogenous and endogenous oxidants may be sufficient to explain the increased 
vascular reactivity observed in this animal model of preeclampsia. Consequently, endothelial 
dysfunction with imbalance between the vasodilator prostacyclin and Endothelium-Derived 
Relaxing Factor, which later has been identified as nitric oxide (NO), and vasoconstrictors 
thromboxane A2 and endothelin-1 might occur. A hypothesis that an increased free 
hemoglobin concentration was the direct cause of vasoconstriction underlying preeclampsia 
has previously been proposed on the basis of its effects on NO (33). Hemoglobin and the 
hemoglobin/haptoglobin complex bind to and inhibit the effects of NO (115).
Plasma iron and ferritin levels are increased in human preeclampsia (116). This was an 
unexpected result of our study to measure the loss of plasma iron concentrations in fasting and 
refed pregnant ewes on the 6th day of experiment. There might be some species differences in 
iron homeostasis in favor of fast iron elimination instead of storage in ferritin molecule which 
process was proved as the ultimate antioxidant defense in other animals and humans during 
oxidative stress caused by heme (109,110,111).
Glucose deprivation in pregnant ewes, with low G6PD activity induced a toxicosis-like 
syndrome very similar to human preeclampsia. The significance of this enzyme deficiency, 
one of the most common genetic enzymatic defects known, in the context of pregnancy was 
assessed previously. Increased rates of abortions, low-birth-weight infants, and puerperal 
drops in red cell volumes were noted in the deficient state (117). Hematologic data in severe 
deficient women suggested slight hemolysis in the first trimester of pregnancy (118). A 
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significant decline in G6PD activity was reported in late gestosis compared to healthy 
pregnant women (119). A decrease in enzymatic activity by half during pregnancy was also 
reported in 65% of pregnant women, while 25% had low activity even at the beginning of 
gestation (120). According to these data, G6PD enzyme activity, as one of the most important 
antioxidant protective systems of red blood cells during oxidative stress, might have a role in 
the pathogenesis of human preeclampsia.
5.6. Discussion of human examinations
Oxidative stress has been suggested as a link between the two-stage model of the 
preeclampsia syndrome: maternal factors cause reduced placental perfusion as stage 1, and 
stage 2 involves an activated maternal endothelium with multisystem disorders (10, 121). The 
enzyme xanthine oxidoreductase (XO/XD) is a key source of oxidants in many pathological 
processes. This enzyme system catalyses the oxidation of hypoxanthine (HX) to xanthine (X) 
and to urate (UA), and exists in an innocuous form (xanthine dehydrogenase, XD) in non­
ischemic tissues. However, if the tissues are exposed to metabolic stress, such as hypoxia or 
ischemia, the enzyme is transformed to xanthine oxidase (XO), which can generate the 
oxidants O2", H2O2 and HO during reperfusion (122). The enzyme system is present in the 
endothelial and vascular smooth muscle cells (123, 124), and also in the human placenta, 
localized to trophoblast cells (23). An increase in XO activity has been proposed as a possible 
cause of oxidative stress in preeclampsia (102), and such an increase has in fact been 
measured in the placentae of women with preeclampsia (125). Besides direct inactivation of 
NO as a vasodilator, XO-derived O^" reacts with NO to form a potent oxidant peroxynitrite 
(ONOO*),  which has been detected both within the vasculature and in the vessel walls of the 
placenta after preeclampia (126, 127). The conversion of XD to XO is also induced by 
ONOO" via thiol group (SH) oxidation (128).
XO is additionally involved in the metabolism of methylxanthines and, after administration 
of caffeine as a ‘prodrug’, the conversion of 1-methylxanthine (1MX) to 1-methyluric acid 
(1MU) depends exclusively on the XO activity, independently of XD (94). The caffeine 
metabolic ratio has proved to be a specific indicator of the in vivo XO activity (96,129-131). 
The clinical status of our overweight subjects met the criteria of preeclampsia syndrome stage 
1 with the risk of preeclampsia developing.
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The reduced plasma level of free SH groups in pregnancy, even without a hypertensive 
disorder, are in agreement with the conclusion of a previous study that a pro-oxidant state is 
present in healthy pregnancy, with reduced plasma thiols (132).
A significant enhancement of the levels of lipid peroxidation products was also measured 
analogously in the pregnancy-induced hypertensive versus the normotensive subjects, as in 
other studies, in both plasma and placenta samples (133). Placental mitochondria enriched 
with polyunsaturated fatty acids may be the sources of the abnormally increased lipid 
peroxidation in the maternal circulation, while increases in both the amount and the oxidative 
potential of the mitochondria have been demonstrated in the preeclamptic versus the normal 
placenta (134).
The higher sum of the all purine metabolites (HX+X+UA) measured in the plasma samples 
of the pregnant group as compared with the non-pregnant women points to an increased 
purine catabolism even during healthy pregnancy. Recent experimental studies have proved 
that metabolic stress can stimulate the purine catabolism (135). This activation of the purine 
catabolism was established to be a component of the homeostatic protective response of the 
mitochondria to oxidant stress by slowing the progressive mitochondrial dysfunction (135).
While in pregnant subjects the plasma concentration of HX, a substrate for XO was 
increased, in hypertensive patients the levels of UA, the product of XO exhibited a significant 
increase. The increased level of UA in mild hypertensive subjects with normal renal function, 
who are under the more pronounced metabolic stress of pregnancy due to their constitution, 
i.e. overweight or/and with transient diabetes, suggests the concomitant increase in XO 
enzyme activity.
Previous studies have revealed that certain unique pharmacological and biochemical 
features of caffeine make it a useful model substrate probe for XO (94, 96, 129-131). 
Allopurinol treatment caused a specific, dose-dependent inhibition of the conversion of 1MX 
to 1MU with a high correlation to the urinary ratio UA/X+HX (96, 131). The XO activity 
index involves only end-products of the caffeine metabolism, and the exact amount and the 
time of collection of the urine are therefore both relatively unimportant as long as the caffeine 
intake is large enough for reliable measurement of the metabolites (130). Studies on the 
caffeine metabolism in pregnancy revealed that smaller amounts of 1MX and 1MU were 
excreted compared to those of non-pregnant controls whereas their molar ratios were not 
different (136).
26
In a population study on 178 young adults (25.5 ± 7.8 years), the XO activity index proved to 
have a rather consistent value of 0.57 ± 0.13 (mean ± S.D.) (137). Our results in non-pregnant 
women (0.542 ± 0.049; n = 15) or in normotensive pregnant subjects (0.596 ± 0.105; n = 14) 
are in good agreement with these values. However, the index was highly increased in 
pregnant women with mild hypertension (0.849 ± 0.096; n = 16). While 1MU could be 
produced only from 1MX, a shift in favor of 1MU in our present study should have been a 
result of XO activation. Thus, the increased purine catabolism during pregnancy was 
accompanied by a XO activation exclusively in hypertensive pregnant subjects.
In the present clinical study, it was impossible to measure either 02" or ONOO" directly, 
as has been done in previous studies by histochemical methods in the placenta or in the 
plasma and the placenta in normotensive and hypertensive pregnancies (125, 126). As XO 
seems to be a major O2~ producing enzyme in the vascular system, several experiments were 
done to clarify the mechanism of XO regulation of NO. The potentiation of NO-mediated 
vasorelaxation was achieved by a XO inhibitor compound (4-amino-6-hydroxypyrazolo[3,4- 
djpyrimidine) on aortic rings from both rabbits and spontaneously hypertensive rats in dose­
dependent manner (138). Intravenous injection of the same compound or pretreatment with 
tungsten diet normalized the characteristic elevation of mean arterial pressure in 
spontaneously hypertensive rats by the elimination of the increased oxyradical production and 
detectable XO activity (138, 139).
The role of xanthine oxidase in human plasma H2O2 production was also reported (140), 
and a close correlation between H2O2 concentrations and the mean arterial pressure was 
proven both in normotensive and hypertensive subjects (141).
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6. Conclusions
— Similarly to previous studies, a sheep disease resembling human preeclampsia and HELLP 
syndrome was induced through simple food withdrawal.
— In the animal model of ewes, hemolysis, secondary to hypoglycemia and low glucose-6- 
phosphate dehydrogenase activity, precedes the symptoms of the preeclampsia-like illness in 
ewes and may trigger the development of the animal disease, which is similar to human 
preeclampsia.
— Pentoxifylline and allopurinol proved to be effective in the prevention of more severe 
preeclampsia-like complications. Although the drugs were not completely effective in 
protecting the animals against certain signs of the illness, organ manifestations (liver and 
kidney involvement, platelet consumption and hypertension) were reduced and fatal 
consequences prevented by simple oral medication. The well-known effect of PTX on 
microcirculation and the inhibition of xanthine oxidase by AP as well as the enhanced 
induction of heme oxygenase may be important points in maintaining normal endothelial 
function and vascular tone regulation during sheep pregnancy.
— Our study showed that elevated in vivo enzyme activity of xanthine oxidase can be 
measured in mild hypertensive pregnant subjects, thus providing additional evidence for the 
putative role of XO as a source of free radicals in human preeclampsia.
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Tablet. Effects of pentoxifylline and allopurinol treatment on changes in plasma albumin, urea nitrogen and creatinine as well as total urine
protein in preeclampsia-like disease in ewes.
Initial value Value at maximal 
change(day)
Initial value Value at maximal 
change(day)
Initial value Value at maximal 
change(day)
Initial value Value at maximal 
change(day)
Group Control 
n = 5
Fasting 
n = 5
Fasting, pentoxifylline-treated 
n = 5
Fasting, allopurinol-treated 
n = 5
Albumin
(g/1)
36.8 ±0.7 36.1 ±0.8
(4)
36.5 ±0.7 32.3 ±1.8*
(5)
37.1 ± 1.3 34.6 ± 1.2 (-)
(4)
35.9±0.8 34.5 ± 1.7 (-)
(4)
Urine protein
(mg%)
51.5 ±8.5 63.2 ±9.4
(6)
48.5 ±8.3 215.1 ±35.6**
(5)
54.0 ±6.5 153.0 ± 12.9**  (+)
(6)
39.8 ±6.5 165.8 ± 19.4**  (+)
(6)
Urea nitrogen
(mmol/1)
8.15 ±0.35 10.0 ± 1.1
(1)
7.98 ±0.18 13.87 ±2.20
(1)
8.28 ± 0.18 15.92 ±3.6
(1)
8.25 ±0.31 15.80 ±4.5 (t)
(2)
Creatinine
(pmol/l)
95.5 ±2.8 115.8 ± 19.7
(2)
90.7 ±2.6 217.0 ±55.4*
(2)
93.3 ±3.2 153.6 ± 25.4 (-)
(1)
99.6 ±4.4 182.5 ± 45.4*  (-)
(2)
Fasting: 96 hours from day 0 to day 4. In the fasting, pentoxifylline-treated group sheep were treated with 15 mg/kg/die pentoxifylline, while in the 
fasting, allopurinol-treated group 20 mg/kg/die allopurinol was administered. Significance (*  and **)  was calculated by multiple-choice ANOVA 
followed by pairwise comparison using Tukey’s test (p < 0.05 and p < 0.01). The occurrence of pathologic changes was noted in the case of either the 
pentoxifylline- or allopurinol-treated, fasting groups: either they arose later (f); or the amount of change was less (-); or the alteration was less and 
appeared later (+), when compared to the non-treated, fasting group. Values are given as mean ± standard deviation.
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Table 2. Demographic characteristics of the study population (mean ± SD)
Non-pregnant Normotensive Hypertensive
controls pregnant pregnant
patients patients
n=15 n=14 n= 16
Maternal age (yr) 25.2 ± 1.8 23.2 ± 2.2 24 ± 3.2
Gestational age (wk) - 35.2 ± 1.3 35.5 ± 2.3
Parity - 1.2 ±0.2 1.5 ±0.3
Body weight (kg) 61.5 ±1.9 69.5 ± 1.2 82.7 ±1.5*
Prepregnant body weight (kg) - 60.3 ± 1.4 67.3 ±1.8*
Blood pressure (mm Hg) 109/70±9/7 113/73±8/8 154/94±17/7*
Prepregnant blood pressure (mm Hg) - 110/70±9/6 114/74±13/6
* p < 0.05 versus normotensive pregnant patients.
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Table 3. Concentrations of some biochemical parameters in the plasma and in the whole 
blood of the study population (mean ± SD)
Non-pregnant Normotensive Hypertensive
controls pregnant pregnant
patients patients
n= 15 n=14 n= 16
Plasma values
Creatinine (pM) 58 ±12 47 ±13 63 ±8
Urea N (mM) 4.3 ± 1.1 3.8 ± 0.9 4.5 ± 1.2
Free sulfhydryl groups (U/L) 388 ±48 262 ± 42* 220 ±58*
Conjugated dienes (OD, 233 nm) 0.52 ± 0.26 0.82 ±0.31 1.70 ±0.32*#
Fluorescent lipids (OD, 430 nm) 49.4 ± 19.2 68.67 ±28.2 136.8 ± 57.4*#
Whole blood values
Total haemoglobin (mM) 8.2 ± 0.4 7.8 ±0.6 7.5 ± 1.0
Carboxyhemoglobin (pM) 68.5 ± 25 63.7 ±32 69.2 ± 16
* p < 0.05 versus non-pregnant controls; # p < 0.05 versus normotensive pregnants.
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Figure legends.
Figure 1. The pathogenesis of preeclampsia. Unification of theories.
Abbreviations: RBC: red blood cell, XO: xanthine oxidase, EC: endothelial cell, CK: cytokine
Figure 2. Initial values and values at maximal change in mean arterial blood pressure, 
platelet count and GOT activity: in pregnant, non-fasting (control); fasting: and fasting, 
treated ewes (mean ± standard deviation). Groups: control group; fasting group: 96-hour- 
long fasting period; PTX-treated group: animals fasting 96 hours, medicated with 
pentoxifylline (15 mg/kg/die from day 0 to delivery); AP-treated group: allopurinol-treated 
group fasting 96-hours (20 mg/kg/die allopurinol from day 0 to delivery). Number of animals 
in each group: 5.
2A: Initial values and values at maximal change in mean arterial blood pressure (7 days after 
the beginning of the 96-hour fasting period in fasting and fasting, treated groups). 2B: Initial 
values and values at maximal change in whole blood platelet count (6 days after the beginning 
of the 96-hour fasting period). 2C: Initial values and values at maximal change in plasma 
GOT activity (7 days after the beginning of the 96-hour fasting period).
Values are depicted as mean ± standard deviation. Significance was calculated by multiple­
choice ANOVA followed by pairwise comparison using Tukey’s test (*  p < 0.05, and ** p < 
0.01, versus control group;b p < 0.05, fasting group versus fasting, drug-treated groups).
Figure 3. Changes in plasma indirect bilirubin and total heme in pregnant, non-fasting 
(control) fasting, non-treated ewes, and in fasting, treated ewes (mean ± standard 
deviation). Values are depicted as. 3A: Control group (n = 5). 3B: group fasting 96 hours. 
3C: animals fasting 96 hours (n = 5), medicated with pentoxifylline (15 mg/kg/die from day 0 
to delivery). 3D: allopurinol-treated group (20 mg/kg/die allopurinol from day 0 to delivery) 
fasting 96 hours (n = 5). Significant alterations were calculated by multiple-choice ANOVA 
followed by pairwise comparison using Tukey’s test.
(x p < 0.05 and xx p < 0.01 in the case of indirect bilirubin while * p < 0.01 and ** p < 0.05 in 
the case of total heme, versus control group; b p < 0.05, fasting group versus fasting, drug- 
treated groups).
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Figure 4. Plasma levels of purine metabolites« hypoxanthine (HX). xanthine (X) (A), and 
uric acid (UA) (B) in controls and pregnant subjects without/with hypertension (mean ± 
SEM).
Significance was calculated by ANOVA followed by Scheffe’s post hoc test.
(**  p < 0.01; *** p < 0.001 versus non-pregnant controls; ## p < 0.01 versus normotensive 
pregnant subjects.)
Figure 5. Urinary concentrations of two caffeine metabolites« 1-methyl uric acid (1MU) 
and 1-methylxanthine (1MX) after caffeine intake (mean ± SEM).
Significance was calculated by ANOVA followed by Scheffe’s post hoc test.
*** p < 0.001 versus non-pregnant controls; ### p < 0.001 versus normotensive pregnant 
subjects.
Figure 6. Xanthine oxidase activity index (1-methvl uric acid/l-methvlxanthine+1- 
methyl uric acid) in controls and pregnant subjects without/with hypertension
Abbreviations: 1MU: 1-methyl uric acid, 1MX: 1-methylxanthine. Mean values are indicated. 
Significance was calculated by ANOVA followed by Scheffe’s post hoc test.
(***  p < 0.001 versus non pregnant controls; ### p < 0.001 versus normotensive pregnant 
subjects.
Figure 1.
Fetal Compromise
A A
Maternal Outcome
Severe Disease
I
I
I
Mild Disease
I
I
I
Hypovolemia <- Vasoconstriction Platelet Aggregation
I
I 
I
I 
I
I 
I
Balance
RBC damage and 
hemolysis "
EC Dysfunction
EC Adhesion 
Molecules 
(neutrophil 
recruitment)
Increased activity of XO and 
cytokine-production, leading to 
^^xidative stress
■Bad' EndotheW
presence of underlying disorders: 
(maternal susceptibility genes)
• chronic hypertension
• thrombophilie disorders
• diabetes mellitus, etc.
▼
Placental
Ischemia
R Acute
Atherosis 1
lipid peroxydation
Immune Maladaptation 
------------------------------- ? 
Genetic Conflict
Shallow Trophoblast
Invasion in
Spiral Artheries
•abnormal decidual CK activity
Figure 2.
I I Control Failing PTX I '• ' 1 AP-treatod
-treated
B
I I Control Footing iS PTX AP-treated
-treated
c
I I Control Footing PTX HBBH AP-treated
-treated
Figure 3.
A B
M Bilirubin /rmol/l (y1) “Heme gmol/l (y2) BBilirubin pmol/l (y1) “Hemepmoi/I (y2)
c D
[')Bilirubin pmol/l (y1) “ Heme jumol/l (y2) B Bilirubin/rmol/l “ Heme jrmol/l (y2)
Figure 4.
A
UA □ B
without with
hypertension
n = 15 n = 14 n = 16
Figure 5.
1MU □ 1MX
Controls Pregnant subjects
without with
hypertension
n=15 n=14 n = 16
